Articoli con mandati relativi all'accesso pubblico - LUIS GONZAGA PAZ-ARES RODRIGUEZUlteriori informazioni
TotaleGovernment of SpainNIHNIHRCancer Research UKEuropean CommissionBanking Foundation "la Caixa"DoDNHMRCCIHRBMBFMRCDFGEMBLINSERMBreast Cancer Now, UKWorldwide Cancer Research, UKLung Cancer Research Foundation, USASNSFHHMINSERCNSFCSFIFCTBBSRCMSFHRANRKWFGoverno ItalianoLUNGevity Foundation, USAV Foundation, USADamon Runyon Cancer Research FoundationCPRITAlex's Lemonade Stand
Non disponibili pubblicamente: 18
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
Mandati: Government of Spain
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ...
The lancet oncology 22 (7), 959-969, 2021
Mandati: US National Institutes of Health
Identification of proteomic signatures associated with lung cancer and COPD
MD Pastor, A Nogal, S Molina-Pinelo, R Melendez, A Salinas, ...
Journal of proteomics 89, 227-237, 2013
Mandati: Government of Spain
Extensive-stage small-cell lung cancer: first-line and second-line treatment options
J Zugazagoitia, L Paz-Ares
Journal of Clinical Oncology 40 (6), 671-680, 2022
Mandati: Government of Spain
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
C Rolfo, AF Cardona, M Cristofanilli, L Paz-Ares, JJD Mochon, I Duran, ...
Critical Reviews in Oncology/Hematology 151, 102978, 2020
Mandati: Government of Spain, Lung Cancer Research Foundation, USA
Targeting EGFR in lung cancer: current standards and developments
A Díaz-Serrano, P Gella, E Jiménez, J Zugazagoitia, ...
Drugs 78, 893-911, 2018
Mandati: Government of Spain
Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review
MG Krebs, U Malapelle, F André, L Paz-Ares, M Schuler, DM Thomas, ...
JAMA oncology 8 (12), 1830-1839, 2022
Mandati: US National Institutes of Health, Lung Cancer Research Foundation, USA
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
I Otano, AC Ucero, J Zugazagoitia, L Paz-Ares
Nature reviews Clinical oncology 20 (3), 143-159, 2023
Mandati: Government of Spain
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small …
T Wehler, M Thomas, C Schumann, J Bosch-Barrera, NV Segarra, ...
Lung cancer 108, 212-216, 2017
Mandati: Government of Spain
Blood predictive biomarkers for patients with non–small-cell lung cancer associated with clinical response to Nivolumab
MT Agulló-Ortuño, Ó Gómez-Martín, S Ponce, L Iglesias, L Ojeda, I Ferrer, ...
Clinical lung cancer 21 (1), 75-85, 2020
Mandati: Government of Spain
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
J Zugazagoitia, A Gómez-Rueda, E Jantus-Lewintre, D Isla, C Camps, ...
Lung Cancer 134, 72-78, 2019
Mandati: European Commission, Government of Spain
Proteomics identifies ubiquitin–proteasome targets and new roles for chromatin-remodeling in the Arabidopsis response to phosphate starvation
J Iglesias, M Trigueros, M Rojas-Triana, M Fernández, JP Albar, R Bustos, ...
Journal of Proteomics 94, 1-22, 2013
Mandati: Government of Spain
PTEN loss confers resistance to anti–PD-1 therapy in non–small cell lung cancer by increasing tumor infiltration of regulatory T cells
F Exposito, M Redrado, M Houry, K Hastings, M Molero-Abraham, ...
Cancer Research 83 (15), 2513-2526, 2023
Mandati: Government of Spain
A patent review of FGFR4 selective inhibition in cancer (2007-2018)
A Quintanal-Villalonga, I Ferrer, S Molina-Pinelo, L Paz-Ares
Expert Opinion on Therapeutic Patents 29 (6), 429-438, 2019
Mandati: Government of Spain
Treatment rationale and study design for the RELAY study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with epidermal …
EB Garon, M Reck, L Paz-Ares, S Ponce, JC Jaime, O Juan, E Nadal, ...
Clinical Lung Cancer 18 (1), 96-99, 2017
Mandati: Government of Spain
Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
C Gridelli, P Baas, F Barlesi, F Ciardiello, L Crinò, E Felip, S Gadgeel, ...
Clinical Lung Cancer 19 (4), 301-314, 2018
Mandati: US National Institutes of Health
SOLTI-1904 ACROPOLI TRIAL: Efficacy of Spartalizumab Monotherapy Across Tumor-Types Expressing High Levels of PD1 mRNA
A Prat, L Paz-Ares, M Juan, E Felip, E Garralda, B González, A Arance, ...
Future Oncology 18 (34), 3791-3800, 2022
Mandati: Banking Foundation "la Caixa", Cancer Research UK
Necitumumab: a new option for first-line treatment of squamous cell lung cancer
E Jimenez Aguilar, J Zugazagoitia Fraile, L Paz-Ares Rodriguez
Expert Opinion on Drug Metabolism & Toxicology 14 (8), 765-772, 2018
Mandati: Government of Spain
Disponibili pubblicamente: 144
Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
Mandati: US National Institutes of Health
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ...
New England Journal of Medicine 373 (2), 123-135, 2015
Mandati: US National Institutes of Health
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software